CellBio

CellBio

ISSN Print: 2325-7776
ISSN Online: 2325-7792
www.scirp.net/journal/cellbio
E-mail: [email protected]
"Treatment of COVID-19 by Controlling the Activity of the Nuclear Factor-Kappa B"
written by Mahmoud Saad Mohamed Elkhodary,
published by CellBio, Vol.9 No.2, 2020
has been cited by the following article(s):
  • Google Scholar
  • CrossRef
[1] Chemical and spectroscopic characterization of (Artemisinin/Querctin/Zinc) novel mixed ligand complex with assessment of its potent high antiviral activity …
Megharbel, SH Qahl, B Albogami, RZ Hamza - PeerJ, 2024
[2] COVID-19: A novel holistic systems biology approach to predict its molecular mechanisms (in vitro) and repurpose drugs
DARU Journal of …, 2023
[3] Exploring NFκB pathway as a potent strategy to mitigate COVID-19 severe morbidity and mortality
Journal of Public …, 2022
[4] Artemisia Extracts and Artemisinin-Based Antimalarials for COVID-19 Management: Could These Be Effective Antivirals for COVID-19 Treatment?
Molecules, 2022
[5] Correlations between Cytokine Levels, Liver Function Markers, and Neuropilin-1 Expression in Patients with COVID-19
Vaccines, 2022
[6] Exploring NFkB pathway as a potent strategy to mitigate COVID-19 severe morbidity and mortality
Journal of Public …, 2022
[7] Artemisia annua L. and its derivatives: Their antiviral effects on COVID-19 and possible mechanisms
Journal of …, 2022
[8] Vinpocetín a jeho klinické implikácie v súčasnej psychiatrickej praxi
Psychiatr. prax, 2021
[9] Molecular dynamics simulation and docking studies reveal NF-κB as a promising therapeutic drug target for COVID-19
2021
[10] The potential role of cytokine storm pathway in the clinical course of viral respiratory pandemic
Biomedicines, 2021
[11] Dimethyl Fumarate Can Enhance the Potential Therapeutic Effects of Epidermal Neural Crest Stem Cells in COVID-19 Patients
2021
[12] Endothelial cell dysfunction, coagulation, and angiogenesis in coronavirus disease 2019 (COVID-19)
2021
SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top